AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY

25 YEAR HISTORY

1969 - 1994

Written by Alphonse J. Ingenito, Ph.D., FCP

October, 1994
FROM 1969 to 1994

by

Alphonse J. Ingenito, Ph.D.
Professor of Pharmacology
School of Medicine
East Carolina University
Greenville, NC 27858

(Written on the occasion of the 25th Anniversary of the founding of ACCP and the 23rd Annual Meeting, Orlando FL, Oct. 1994)

[Note from the author - The following account of the College's history was drawn from written documentation of the events, as per (1) official minutes of the Board of Regents and Annual Business meetings, (2) copies of correspondence and records made available by our Executive Directors and from former Officers and Regents, (2) ACCP Newsletters, (3) publications in the Journal of Clinical Pharmacology and other journals, (4) interviews and correspondence with Past-Presidents and Officers and former Regents, and (5) my own personal notes and correspondence as 2-term Regent, and chair of various ACCP Committees since my election as a Charter Fellow of the College in 1971. Because of its brevity, I have been unable to detail, or even mention, the contributions of the very many members, fellows, officers, employees, advisors and supporters of the College during the past 25 years. I express my apologies to them with the hope that the omissions may be rectified later with the anticipated writing of a more detailed, narrative account of the College's history. Each living Past-President and a few selected older Regents were asked to review the accuracy of this account. I am very grateful to them for their assistance.

This writing is divided into: (1) a consideration of the circumstances and personalities surrounding the origins of the present ACCP, culminating with its incorporation in 1969; (2) a year-by-year summary of major events, developments and advancements made by the College; (3) listings of Officers, Regents and Executive Directors serving from 1969 to 1994; (4) a listing of honorees who were presented specific awards by ACCP over this time period; and (5) a listing of Annual Meetings, Frontier Symposia and other educational activities of the College. Finally, a list of references is provided for those interested in more detailed information.]
Origins of the American College of Clinical Pharmacology

The origins of modern clinical pharmacology can probably be traced to the early 1900’s, with the emergence of technology for the efficient synthesis of organic chemicals in pure and sizeable quantities, the rise of the pharmaceutical industry and subsequent decrease in the use of herbal medicines. Federal regulation of drug use, particularly the Food, Drug and Cosmetic Act of 1938, which mandated drug safety, and the Kefauver-Harris Amendment to this Act, in 1962, which mandated requirements for drug efficacy, created a need to establish the efficacy of newly introduced drugs. This focused attention on qualifications and training of personnel to conduct these trials and emphasized the importance of the new, but clearly emerging discipline of clinical pharmacology. Many pharmacologists and clinicians are identified with pioneering efforts in establishing safety and efficacy of drugs via controlled clinical trials in humans. For ACCP, the most influential was Dr. Harry Gold of the Department of Pharmacology at Cornell Medical College, New York City. Gold was a clinician, researcher and teacher there who, along with Doctors McKeen Cattell and Nathaniel T. Kwit, carried out important clinical investigations which established a firm basis for the efficacy of digitalis glycosides in congestive heart failure. These studies included both animal and human subjects. They also provided strong evidence that the use of xanthines in human angina pectoris was without merit. Dr. Cattell was then Chairman of the Department of Pharmacology at Cornell and Dr. Kwit was a clinician at Cornell. Each of these individuals had an important organizing role in forming a society called the American College of Clinical Pharmacology and Chemotherapy (ACCPC) which was the forerunner of ACCP.

The pre-eminent role of Dr. Duncan E. Hutcheon in organizing ACCPC, along with Doctors Cattell, Gold, Kwit and Theodore Greiner, in 1963 must be recognized. Dr. Hutcheon was then on the faculty in Pharmacology at the New Jersey College of Medicine. He recognized the need for an organization primarily devoted to increasing knowledge and developing high standards for the emerging discipline of clinical pharmacology as it related to drug therapy. Dr. Hutcheon felt that this organization should serve the needs of many diverse workers in the field; those with varying biomedical degrees, training and background who shared a common interest in the basis of rational drug therapy. He worked tirelessly to recruit members for the new organization. The ACCPC organizers were joined at this time by Dr. Benjamin Calesnick, a clinician, teacher and researcher who was on the faculty of the Department of Pharmacology at Hahnemann Medical College and Director of its Section of Human Pharmacology. Dr. Calesnick was, at the time, engaged in efforts to establish teaching programs within schools of medicine designed to help train clinical investigators involved in human drug studies. Dr. Calesnick foresaw a great need for qualified, well-trained investigators, in view of impending FDA oversight of trials of new drugs, in keeping with the requirements of the newly-enacted Kefauver-Harris Amendment of 1962. He wrote a proposal for such training which, in addition to educational curricula, contained a suggestion for board certification in clinical pharmacology. He corresponded with many established pharmacologists, particularly members of the American Society for Pharmacology and Experimental Therapeutics, to determine their reaction to the proposal. He met with many negative responses, in part because some considered the field as too young and undeveloped for such initiatives. However, many respondents encouraged his efforts. He found support among the early developers of ACCPC and he was recruited into the organization.
In his consideration of the history of the development of early ideas and organizations in clinical pharmacology, Aagaard\(^1\) discusses the sequence of events which led to the eventual merger of ACCPC and the American Therapeutics Society (ATS) in 1969. ATS was by then a very large group of physicians, originally founded in 1900, whose original purpose was "the study and advancement of therapeutics\(^1\)". Dr. John H. Moyer III, who was active in both ATS and ACCPC, and who served as President of both groups in the mid-1960's, became interested in merging the two groups and began negotiations between the governing bodies of both societies. As Aagaard\(^1\) relates, and as confirmed by Dr. Calesnick, there was a group within ACCPC who believed that ATS was not strong scientifically, and this ACCPC group strongly opposed the merger. One surmises that the early founders of ACCP were among those in opposition to the merger. Reasons for this opposition were later explained in a 1971 editorial in the Journal of Clinical Pharmacology by Harry Gold\(^2\). Gold made a distinction between clinical pharmacology on the one hand, and therapeutics on the other. He stated that clinical pharmacology is drug-oriented while therapeutics is patient-oriented. He regarded them as entirely different disciplines, which, while interdependent, they differ in many respects, including training. He explained that while clinical pharmacology deals with the science of how drugs act, their toxic effects, pharmacokinetics, metabolism, etc., therapeutics concerns itself mainly with controlling the disease process in a practical sense. The main functions of ATS were determined to be sufficiently divergent to those of ACCPC, according to Gold, to originate ACCPC in 1963, and to resist later attempts to merge them. (The author has corroborated Dr. Gold's interpretations with Dr. Calesnick, who, as an ACCPC member, was aware of the issues at that time.) The two societies eventually did merge, in December of 1969, and adopted the name "American Society for Clinical Pharmacology and Therapeutics" (ASCPT), which exists as such today. Some within ACCPC who opposed the merger subsequently formed the present American College of Clinical Pharmacology (ACCP) in 1969. (It should be noted here that our use of the abbreviation ACCP has, at times, been challenged by other organizations who also use it, such as the American College of Chest Physicians and the American College of Clinical Pharmacy. While this may lead to confusion by those unfamiliar with the organizations, we know of no compelling reasons, in the absence of existing copyrighting of the "ACCP" designation, why each organization cannot continue to use the same abbreviation, as familiar to their membership).

The legal incorporation of ACCP was effected on September 11, 1969, in the District of Columbia. The articles of incorporation list Doctors Duncan E. Hutcheon, McKeen Cattell and Harry Gold as the initial board of directors. The objects of the College were listed as "to promote and advance the science of clinical pharmacology and chemotherapy in all its phases, to establish high standards of clinical investigation in this field of endeavor, to issue publications for these purposes and to engage in other appropriate educational efforts." Membership categories were listed as Member, Associate Fellow, Fellow and Honorary Fellow. Only Fellows were entitled to all the privileges of the College, including holding office and voting for officers.

The first recorded meeting minutes of the newly incorporated ACCP were those of an Executive Committee meeting on Nov. 13, 1969, held at 7 E. 82nd St. New York (apparently the office of Dr. Harry Gold). Doctors McKeen Cattell, Harry Gold, Duncan Hutcheon, Nathaniel Kwit and Philip Reichert were in attendance, with Dr. Hutcheon presiding. Dr. Hutcheon reviewed the steps leading to the incorporation of the College. He emphasized the
importance of establishing a leadership role for ACCP to meet the critical problems of drug therapy in man. He considered it important for ACCP to promote curricular planning for pharmacology courses in schools of medicine, which, at the time, had been adversely affected by the sweeping tide of curricular reforms the 1960's. Dr. Cattell advised that in seeking members, the College should not be restricted towards any specific group of scientists, while Dr. Gold felt it important to recruit basic pharmacologists and those with experience in biostatistics. Dr. Reichert reported that he had started the search for a headquarters office for the College, possibly in the Empire State Building. Dr. Cattell stated that the New York Academy of Medicine building on E. 103rd St. might have available space. It was agreed that the letters "FCP" would represent the high standards expected of ACCP Fellows. Dr. Reichert requested that all present come to the next meeting with a list of objectives of the College.

The objectives for ACCP submitted at the next meeting by Doctors Cattell and Hutcheon stressed establishing a role for clinical pharmacology as a professional entity, promoting education, training and research in the field and sponsoring a publication having a major interest in clinical pharmacology. Additional aims proposed by Dr. Reichert called for ACCP to serve as an advisory board for liaison with the U.S. Congress and FDA, including a role in evaluating new drug proposals. Dr. Kwit pointed out the need to draw up a Constitution and By-Laws.

1970-1971

- Temporary ACCP office at N. J. College of Medicine.
- Officers meet on monthly basis in New York City.
- First Board of Regents appointed for 5-year terms: Doctors Benjamin Calesnick, Herbert Kupperman, W. Walter Oppelt, Leonard Proctor and Donald Robinson.
- First Officers elected: President-Dr. Duncan E. Hutcheon, Vice-President-Dr. Benjamin Calesnick, Secretary-Dr. William D. Sharpe, Treasurer-Dr. Nathaniel T. Kwit.
- Charter group of about 50 Fellows selected by invitation.
- First constitution drafted. Functions of College stated and criteria for Member and Fellow categories defined.

1972

- Regents concentrate on defining ACCP's role and expanding membership. Prominent clinical pharmacologists recruited.
- Dr. Charles A. Walton spearheads efforts to set standards for Pharm. D. members of ACCP³.
- Negotiations begun between Dr. Leonard Proctor and Dr. Cattell for eventual ownership of J. Clin. Pharmacol. by ACCP.
- Death of Dr. Harry Gold announced in April, 1972⁴.
- Membership of College now 145 (105 Fellows, 40 Members).
First Annual Meeting held in April in Atlantic City, NJ. Workshops held on teaching, lab functions, drug surveillance and drug utilization review. Dr. Joseph DiPalma makes strong case for clinical pharmacology as a specialty and calls for board certification of clinical pharmacologists.

1973-1975

2nd Ann. Meeting, April 1973, Atlantic City, 2 full days, with scientific podium sessions for first time. 20 papers presented.

August, '73, possible acquisition of J. Clin Pharmacol. referred to Publications Committee for recommendation.

Third Annual Meeting, April 1974, Atlantic City, 2 days; education themes predominate.
Standing Committees on Constitution and By-Laws, Professional Affairs, Long-Range Planning, Membership, and Finance appointed.

Dr. Raymond Ahlquist (Education Committee) organizes tape and slide educational programs in basic and clinical pharmacology.

Fourth Annual Meeting, April, 1975, Atlantic City, 2 days, again with educational themes. Luncheon award session for 1st time; Harry Gold Award presented and Honorary Fellowship awarded to Nobel laureate Dr. Julius Axelrod.

Dr. Duncan Hutcheon assumes increasing responsibilities as the Journal's Assistant Editor, to Dr. Cattell.

1975 - College office moves to N.Y. Academy of Medicine bldg. at #2 E. 103rd St. Mrs. Barbara Renaud is part-time secretary.
Arrangements made to give CME/CEU credits at ACCP Annual Meetings by sponsoring medical and pharmacy schools.

1976-1977


April, 1976 - Dr. Benjamin Calesnick becomes 2nd President of ACCP.

Fifth Annual Meeting, Philadelphia, Apr./May 1976. Symposia on bioavailability and on legal aspects of clin. pharmacol.; 3 scientific sessions and 46 papers presented; 185 attendees.

Aug. 1976 - Dr. Duncan Hutcheon incorporates American Board of Clinical Pharmacology.

1977- Academic Affairs Committee (Dr. Peter Regna, Chair) appointed to look after public affairs, regulatory issues, etc.
1977- Constitution and By Laws Committee revises constitution for first time.

1977- Dr. Hutcheon begins planning for American Board of Clinical Pharmacology, using own funds.

1977- Membership dues raised from $25 to $35 and Fellows from $40 to $50.

1978

Revised constitution and by-laws approved by membership.
Journal goes from bi-monthly to monthly under Dr. Hutcheon. Advertising accepted for first time. Alternate publishers considered.
Dr. Raymond P. Ahlquist becomes 3rd ACCP President.
Slate of 9 candidates proposed for 7 openings for Bd. of Regents.
April 1978 - 7th Annual Meeting held in San Francisco conjointly with Associates of Clinical Pharmacology.; 2 days, 2 symposia, 5 scientific podium sessions and 37 papers presented.
Arrangement for ACCP Office at NY Acad. Med. is terminated. Search for new office and possible Executive Director begins. Nov. 1978 Dr. Mark Hurwitz, President of Association Dynamics, Princeton, NJ, appointed Office Manager. ACCP office moved to Princeton. Dr. Hurwitz plans new strategies for membership and financial donations.
Dr. Ahlquist stresses educational roles for ACCP and appoints Dr. A. J. Ingenito to Chair Education Committee. Speakers Bureau and drug therapy symposium at Acad. Fam. Pract. meeting planned. Concept of education foundation within ACCP discussed.

1979

New recruiting brochure created and mailed to many prospective members.
Publications committee (Dr. Greenblatt, Chair) suggests changes in Journal format and reorganizes Editorial Board.
Goals and priorities for ACCP requested by Dr. Hurwitz.
Slate of new Regents nominated.
May, 1979 - 8th Annual Meeting in Washington, DC; 3 symposia, 2 afternoons of roundtable discussions on regulatory affairs; 4 scientific podium sessions with 49 papers presented.
Discussions of the status of the American Board of Clinical Pharmacology prompt Dr. Elliot Vesell to advise against any unitary sponsorship of the Board without the support and cooperation of ASCPT and ASPET. ASPET suggests a Tripartite Task force composed of 6 members from ACCP, ASCPT and ASPET be convened to work out issues involving the Board. This group begins deliberations.
Dec. 1979 - Dr. Mark Hurwitz is replaced by Mr. William Chaveas who was appointed Executive Director. ACCP headquarters offices moved to College of Physicians of Philadelphia building, 19 So. 22nd St. Philadelphia.

1980

Survey of educational materials available for teaching clinical pharmacology prepared by Education Committee. Extensive commitment to formal production of educational materials deemed premature by Regents.
Dr. Elliot Vesell elected next President of ACCP.
Constitutional amendment committee appointed to review policies for election of Regents.
Dr. Larry Allen appointed Chair of ad-hoc Committee on Pharmacokinetic Nomenclature. (Manual published by ACCP in 1982).
9th Annual Meeting held in Washington DC in May; features 3 symposia, a roundtable discussion on clin. pharmacol. board and several scientific sessions with 26 papers presented.

Dr. Harold Dettelbach mounts strong membership drive by personal contacts to prospective members by himself and other Regents.

1981

Regents reexamine policy of annual meetings in Spring and at time and place related to AFCR meetings. Continued meeting close to AFCR meeting was endorsed.

Evaluations of Journal and its operations were continued. Alternate publishers continued to be suggested and considered.

10th Annual Meeting held in Philadelphia, 4/29 and 5/1 at Phila. College of Physicians. It featured 2 symposia and 4 scientific sessions with 37 papers presented. Sept. - First Frontiers Symposium on the topic of new cephalosporins was held in Philadelphia, as planned by Doctors Harold R. Dettelbach and Harold C. Neu, and was very successful, with over 300 attendees. The proceedings of this symposium were published in textbook form by the College.

1982

ACCP collaborates with other professional organizations:
- consulted by FDA on guidelines for hypnotic drug use
- ACCP joins National Council on Drugs.

Membership now at 567

Five new Regents elected for 5-year terms.

Dr. Michael Rosen becomes next ACCP President; sets following priorities:
  a) preparation of long term goals statement
  b) expansion of ACCP’s educational roles

Visiting professorship program begun (partly funded by ACCP).

Committee appointed to review Journal operations and report within 9 months (Dr. Brian Hoffman, Chair).

Annual Meeting to be moved to fall to avoid conflicts with other meetings.

1983

Dr. Hutcheon reappointed Journal Editor for 3-year term.

Dr. McKeen Cattell, ACCP founder, dies Feb. 8.

Pres. Rosen introduces idea of President-Elect office in place of Vice-President, to assure smooth transition of office.

Annual Meeting held in May, in Wash. D.C. Poster sessions held for 1st time. 56 scientific papers presented.

Report of Journal Committee submitted, and is complementary to Dr. Hutcheon and Journal’s operations but suggests following changes:
  a) need for better quality papers
  b) publication in larger "A" size
c) appointment of section editors
d) consider alternate publishers
e) more, but still limited advertising

1984

Concern about static membership statistics over past few years. Retention the main problem.
Annual Meeting in Philadelphia in October. 84 papers presented.
Dr. Harold Dettelbach becomes next ACCP President.

1985

25th Anniversary year of J. Clin. Pharmacol. is accompanied by sweeping changes in Journal’s operations. Regents appoint Dr. John C. Somberg Editor in Chief. Dr. Deborah Keefe becomes Assistant Editor and Dr. Hutcheon becomes Emeritus Editor.
American Board of Medical Specialties rejects concept of a board in clinical pharmacology as a sub-specialty board under internal medicine. Free-standing board seems likely.
Annual Meeting again in Philadelphia in October, 109 papers presented.
Membership now at 517.

1986

New main office for ACCP now in Wayne, PA (Phila. suburb). Mr. William Chaveas continues as Executive Director.
Revised constitution approved by fellowship.
Repeat Frontiers Symposium on antibiotics again attracts many.
Membership elects Regents for 4 positions. Proposal made to nominate more Regents than available openings, allowing choice.
Annual Meeting again held in Philadelphia, in Oct., conjointly with the Associates of Clinical Pharmacology. 105 papers were presented.
Dr. Andrew Whelton takes office as ACCP President.
ACCP agrees to purchase the American Board of Clinical Pharmacology from Dr. Hutcheon, reimbursing him for past expenses.

1987

Vacillation and lack of progress on Board by Tripartite group is a cause of serious concern to Regents. Some urge ACCP continue alone on Board. Accreditation of non-MD’s still an unresolved and contentious issue.
Contracts of Mr. Chaveas, Dr. Somberg and Dr. Keefe are extended.
New publisher of the Journal is J. B. Lippincott Co., Philadelphia.
Survey of clinical pharmacologists in U.S. to be done by Dr. Wilson.
Annual Meeting in Philadelphia in fall held conjointly with Int. Society of Dermatology, with 95 papers presented.

Dr. George Porter's Education Committee active in planning/overseeing a variety of educational offerings sponsored by ACCP.

Dr. Dettelbach's fundraising efforts contribute to good financial picture this year for ACCP.

Guidelines for ACCP Honors and Awards drafted by Dr. A. J. Ingenito.

Membership now stands at 672.

1988

Tripartite Task Force agrees to purchase Board from ACCP. First exam planned for May, 1988. Autonomous Board to be composed of 6 members from each society.

Dr. Donald Weidler organizes 1st ACCP regional Chapter in Miami and moves forward to start other regional Chapters. Dr. Rex Woo-Ming leads in recruiting efforts for local chapters. Membership is bolstered by this effort and is now at 774.

Annual Meeting in Orlando, Fl. in Oct., conjointly with the American Assoc. of Pharmaceutical Scientists (AAPS), with over 400 registrants. Record number of 207 abstracts were presented. Sir James Black, recent Nobel Laureate, is honoree, with 3 others.

Annual dues of Fellows now $95.00; Members $70.00 and Associate Members $60.00.

1989

Progress continues towards scheduling 1st Board examination.

Dr. Kazuo K. Kimura elected ACCP President and outlines priorities:
  a) Completion of development of Board;
  b) doubling of the membership within 2 years;
  c) developing strong educational programs for CME and CEU credits;
  d) increasing ACCP/ASCPT/ASPET coordination.

Dr. Wilson's survey of clinical pharmacologists is published¹⁰.

Education Committee to prepare report of possible application to allow ACCP to give CME and CEU credits.

Report of Long-Range Planning Committee (Dr. Greenblatt, Chair):
  a) keep ACCP office in Philadelphia area and seek permanent site;
  b) new Executive Director must have business skills;
  c) increase membership to 2,000 in 3 years;
  d) strong fund-raising efforts are needed, and
  e) re-evaluate structure and function of Regents.

Newsletter re-organized by Dr. Larry Allen.

Annual Meeting in Baltimore in October, held jointly with the Associates of Clin. Pharmacol.; featuring 5 symposia and general discussion of the Amer. Board of Clin. Pharmacol. 122 scientific papers were presented and registrations exceeded 300.
1990

- Mr. Chaveas to retire as Exec. Director in Oct. Search for replacement among 125 applications yields 9 finalists. Ms. Joelle Bertolet selected as successor.
- Dr. Moses Chow reports that 4 Regional Chapters now exist (Miami, Augusta, GA, Delaware Valley, PA and Southwest Regional Chapter). Several others reported being formed.
- American Board of Clin. Pharmacol. now independently functioning. First exam scheduled for 5/19/91. Controversy over non-MD certification persists. Dr. Somberg discusses many issues regarding ABMS in series of editorials 11, 12, 13, 14.
- Annual Meeting held in Las Vegas conjointly with AAPS, featuring conjoint symposia, 125 poster presentations and several thousand conjoint registrants.
- Dr. Donald Weidler elected President; stresses glasnóst (openness) and perestroika (restructuring) as key features of his term of office.

1991

- ACCP Regents support certification by ABCP for all doctoral applicants (non-MD’s as well as MD’s).
- Regents propose electing Regents by local chapters.
- Membership now at 1047, with 9 operating regional chapters.
- ACCP considering recommending policies for reimbursement of services of clinical pharmacologists under health insurance plans.
- Annual Meeting in Atlanta; 3 full days, and 6 symposia.

1992

- Increased administrative and salary costs, due to increased committee activities and educational programs, lead to budgetary constraints and other means to retain a sound financial status.
- Local chapters are increasing, with strong attendance at meetings. Garden state (NJ), Gainesville and Tampa Bay Fl, Dallas TX, Ohio and Illinois Chapters reported forming.
- Annual Meeting in Wash. D.C., 3 full days, 11 symposia and a postmeeting teaching clinic. Five awards were presented.
- Membership now stands at 1041.
- Dr. Barry Dvorchik succeeds Dr. Weidler as President. Sets goals as defining who we are, who we serve, what we wish to achieve and resources available to do these.
- Executive Committee selects Ms. Susan Ulrich to replace Ms. Bertolet as Executive Director. College’s offices moved to Yorkville, NY (Utica area).

1993

- College consulted by FDA for input on list of unlabelled uses for approved drugs.
- Election for Regents with multiple choices for positions was held.
- A consultant was hired to effect strategic planning as to mission and aims of ACCP and how best to achieve these. Strong and weak points of the College were identified.
Questionnaire on College and Journal policies is mailed to membership and results of survey are analyzed and published. Survey finds membership is broadly-based as regards degrees, places of occupation, specialty interests, etc. The Journal is highly regarded. Main function of ACCP should be educational and ACCP should not be aligned or merged with other societies.

Membership now at 940.

Annual Meeting held in Boston in Nov. and featured 6 symposia, a 2nd teaching clinic and 4 awards were presented.

Contract with Dr. John C. Somberg, Journal Editor, is not renewed. Regents appoint Dr. Deborah Keefe as Interim Editor.

1994

Regents develop formalized vision and mission statements.

Vision: Improve patient outcome by optimizing therapeutics.

Mission: Continued commitments to education, development of new knowledge, service to membership and to act as a forum for public affairs issues in drug therapy.

Speakers Bureau in planning stages.

Dr. William Wechter ends term of service as Editor of revitalized newsletter. Dr. Michael Jann is new Editor.

Membership now at 962.

ACCP representatives contribute actively to AAMC’s Council of Academic Societies and Council for Education in Clinical Pharmacology.

23rd Annual Meeting held in Orlando FL, 10/6 through 10/8, in celebration of 25th Anniversary of founding of ACCP. Meeting featured 5 symposia, including one on history of clinical pharmacology.

References


Additional Reading on the Origins, Development and Issues Concerning The American Board of Clinical Pharmacology

Kimura, K. K. American Board of Clinical Pharmacology 1976-1989. (A chronological series of events leading to the establishment of the Board, written for the American College of Clinical Pharmacology, 10/6/89 and distributed at the 18th Annual ACCP Meeting, Baltimore, October, 1989; available through the ACCP Office, Yorkville, NY).


AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY FELLOWS WHO HAVE SERVED ON THE BOARD OF REGENTS (Terms of service in parentheses)

Abernethy, Darrell, MD, PhD (86-91)  
Ahlquist, Raymond P., PhD (73-78)  
Apple, Martin, PhD (73-78)  
Aviado, Domingo M., MD (78-83)  
Brands, Allen J., D.Sc. (78-83)  
Browne, Thomas R., MD (84-89)  
Burris, James F., MD (90-95)  
Calesnick, Benjamin, MD (70-75; 79-84)  
Carr, Albert A., MD (88-93)  
Cattell, McKeen, MD, PhD (70-75)  
Cavaliere, Mary B., PhD (79-84)  
Chaikin, Philip, PharmD, MD (93-98)  
Chapman, John E., MD (72-77; 89-94)  
Chow, Moses S.S., PharmD (90-95)  
Colburn, Wayne A., PhD (91-96)  
Cutler, Ralph E., MD (85-90)  
Derendorf, Hartmut, PhD (91-96)  
Dettelbach, Harold R., PhD (80-85)  
Dietz, Albert J., MD, PhD (88-93)  
DVorchik, Barry H., Ph.D. (83-88)  
Frankl, William, MD, (80-85; 93-98)  
Gelfand, Maxwell L., MD (75-80)  
Glasser, Stephen P., MD (90-95)  
Gold, Harry, MD (70-75)  
Graham, Cheryl F., MD (93-98)  
Greenblatt, David J., MD, PhD (79-84; 86-91)  
Hutcheon, Duncan, E., MD, D.Phil. (70-75)  
Ingenito, Alphonse J., PhD (75-80; 83-88)  
Keefe, Deborah L., MD, MPH (84-89; 91-96)  
Kimura, Kazuo K., MD, PhD (82-87)  
Kupperman, Herbert, MD, PhD (70-75)  
Kwit, Nathaniel T., MD (70-75)  
Lathers, Claire M., PhD (86-91)  
Ling, Albert S.C., MD, PhD (80-85)  
MacKichan, Janis J., PharmD (89-92)  
Mayor, Gilbert H., MD (88-93)  
Neu, Harold C., MD (82-87)  
Oppelt, W. Walter Jr., MD (70-75)  
Owen, John A., MD (74-79)  
Piepho, Robert W., PhD (83-88; 91-96)  
Pina, Ileana L., MD (88-91)  
Porter, George A., MD (84-89)  
Procita, Leonard, PhD (70-75)  
Ram, C. Venkata S., MD (88-93)  
Regna, Peter, PhD (78-83)  
Reichert, Phillip, MD (70-75)  
Roberts, Jay, PhD (74-79; 82-87)  
Robinson, Donald, MD (70-75)  
Rosen, Michael R. MD (78-83)  
Sharpe, William D., MD (70-75)  
Smith, Cedric M., MD (93-98)  
Somberg, John C., MD (85-90; 91-94)  
Spector, Reynold, MD (82-85)  
Tarazi, Robert C., MD (84-86)  
Vesell, Elliot, MD (75-80)  
Walton, Charles A., PhD (72-77)  
Wechter, William J., PhD (89-94)  
Weidler, Donald J., MD, PhD (84-89)  
Whelton, Andrew, MD (84-89)  
Wilson, John T., MD (85-90)  
Yakatan, Gerald J., PhD (79-84; 86-91)
OFFICERS OF THE COLLEGE - 1970 through 1994

Ahlquist, Raymond P., Ph.D.
President (78-80)

Kwit, Nathaniel T., MD
Treasurer (70-90)

Calesnick, Benjamin, MD
Vice President (70-76)
President (76-78)

Lathers, Claire M., PhD
Treasurer (90-92)
President Elect (92-94)
President (94-96)

Chapman, John E., MD.
Vice President (80-82; 82-84)

Piepho, Robert W., PhD
Secretary, (94-96)

Chow, Moses S. S., PharmD
Secretary (92-94)

Procita, Leonard, PhD
Vice-President (76-78)

Colburn, Wayne A. PhD
Treasurer (94-96)

Roberts, Jay, PhD
Secretary, (76-78, 78-80)

Dettelbach, Harold R., Ph.D.
Secretary (82-84)
President (84-86)

Rosen, Michael R., MD
President (82-84)

Dvorchik, Barry H., Ph.D.
Secretary (88-90)
President Elect (90-92)
President (92-94)

Sharpe, William D., MD
Secretary (70-76)

Evans, Eleanor, MD
Secretary (80-82)

Vesell, Elliot, MD
Vice President (78-80)
President (80-82)

Greenblatt, David J., MD
President Elect (94-96)

Weidler, Donald J., MD, PhD
President Elect (88-90)
President (90-92)

Hutcheon, Duncan E., MD., D.Phil.
President (70-76)

Whelton, Andrew, MD
President (86-88)

Keefe, Deborah L., MD, MPH
Treasurer (92-94)

Wilson, John T., MD
Secretary (90-92)

Kimura, Kazuo K., MD, PhD
President Elect (86-88)
President (88-90)
<table>
<thead>
<tr>
<th>Executive Directors</th>
<th>Office Title 1975-1992</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renaud, Barbara</td>
<td>(75-78, Office Mgr)</td>
</tr>
<tr>
<td>Chaveas, William F.</td>
<td>(79-91)</td>
</tr>
<tr>
<td>Ulrich, Susan</td>
<td>(92-present)</td>
</tr>
<tr>
<td>Hurwitz, Mark</td>
<td>(78-79, Office Manager)</td>
</tr>
<tr>
<td>Bertolet, Joelle</td>
<td>(91-92)</td>
</tr>
<tr>
<td>No.</td>
<td>Dates</td>
</tr>
<tr>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>1st</td>
<td>4/28 and 4/29/72</td>
</tr>
</tbody>
</table>
2) Eval. of drug safety/efficacy  
Work/Study conferences  
a) Teaching  
b) Lab Methods  
c) Eval. of drug efficacy  
d) Drug Info. Services |
| 3rd | 5/3 and 5/4/74   | Atlantic City    | A.J. Ingenito            | Sym: 1) Teaching therapeutics  
2) Drug-induced carcinogen  
Planning Councils:  
a) Teaching  
b) Lab Methods  
c) Organiz. clin. pharm.units  
d) Drug info. centers  
20 scientific papers |
| 4th | 5/2 and 5/3/75   | Atlantic City    | J.A. Owen                 | Sym: 1) Teaching Therapeutics  
2) Adverse drug react.  
Planning Councils:  
a) Teaching  
b) Clin. Tox. labs  
c) Organizing clin. pharm.units  
16 scientific papers |
2) Clin Phar.& the Law  
46 scientific papers |
2) Industry role in med. ed.  
3) Geriatric clin. pharmacol.  
35 scientific papers |
| 7th | 4/27 and 4/28/78  | San Francisco    | M.A. Apple and M.B. Maggio-Cavaliere | Sym: 1) Drug ther for prim. care  
2) Clin. phar. of drug abuse  
37 scientific papers |
| 8th | 5/3 and 5/4/79    | Wash. DC         | M.B. Maggio-Cavaliere     | Sym: 1) Pharmacist @ bedside  
2) Drug innovation '79  
Roundtable discussions:  
a) Non-commer. IND sponsors  
b) Fed regs on clin invest  
49 scientific papers |
<table>
<thead>
<tr>
<th>Date</th>
<th>Location</th>
<th>Speaker(s)</th>
<th>Symposia</th>
</tr>
</thead>
<tbody>
<tr>
<td>9th 5/14 thru 5/16/80</td>
<td>Wash. DC</td>
<td>D.J. Greenblatt (scientific) Allen Brands (local arrang.)</td>
<td>1) Drug ther. for fam. phy. 2) Clin pharmacy/pharmacol. 3) Use/abuse serum levels Roundtable discussion: Boards in clin. pharmacol. 26 scientific papers</td>
</tr>
<tr>
<td>10th 4/29 thru 5/1/81</td>
<td>Philadelphia</td>
<td>D.J. Greenblatt</td>
<td>1) New drugs &amp; clin. phar. 2) Antineoplastic drugs 37 scientific papers</td>
</tr>
<tr>
<td>11th 5/6 and 5/7/82</td>
<td>Wash. DC</td>
<td>D.J. Greenblatt</td>
<td>1) Drugs and the kidney 2) Drugs in Neurol. Dis. 32 scientific papers</td>
</tr>
<tr>
<td>12th 4/28 and 4/29/83</td>
<td>Wash. DC</td>
<td>G.J. Yakatan</td>
<td>1) Anti-arrhythmic drugs 2) Geriatric pharm. res. 56 scientific papers</td>
</tr>
<tr>
<td>13th 10/18 and 10/19/84</td>
<td>Philadelphia</td>
<td>T.R. Browne</td>
<td>1) New drug deliv. syst. 2) Pediatric clin. phar. 84 scientific papers</td>
</tr>
<tr>
<td>14th 10/17 and 10/18/85</td>
<td>Philadelphia</td>
<td>T.R. Browne</td>
<td>1) New meth. in drug distrib. studies 2) Drug interactions 109 scientific papers</td>
</tr>
<tr>
<td>15th 10/16 and 10/17/86</td>
<td>Philadelphia</td>
<td>D.J. Weidler</td>
<td>1) New regs on cardiovasc. drugs 2) New cardiovasc. drugs 105 scientific papers</td>
</tr>
<tr>
<td>17th 10/31 thru 11/3/88</td>
<td>Orlando</td>
<td>D.J. Weidler</td>
<td>1) Antihypertensives 2) Immunosuppressives 207 scientific papers</td>
</tr>
<tr>
<td>Date</td>
<td>Event Date</td>
<td>Location</td>
<td>Speaker</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>20th</td>
<td>10/13 thru 10/16/91</td>
<td>Atlanta</td>
<td>L.R.C. Moore</td>
</tr>
<tr>
<td>No.</td>
<td>Date</td>
<td>Title</td>
<td>Program Chair(s)</td>
</tr>
<tr>
<td>-----</td>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>I</td>
<td>9/14-9/15/81</td>
<td>New Beta-Lactam Antibiotics: A Review from Chemistry to Clinical Efficacy of the New Cephalosporins</td>
<td>Harold C. Neu</td>
</tr>
<tr>
<td>II</td>
<td>10/4-10/5/82</td>
<td>Calcium Antagonists: The State of the Art and Role in Cardiovascular Disease</td>
<td>Michael R. Rosen</td>
</tr>
<tr>
<td>V</td>
<td>2/4-2/5/85</td>
<td>Applications of Stable Isotopes in Pharmacology</td>
<td>Thomas R. Browne</td>
</tr>
<tr>
<td>VI</td>
<td>5/22-5/23/86</td>
<td>New Directions in Antimicrobial Agents</td>
<td>Harold C. Neu</td>
</tr>
<tr>
<td>VII</td>
<td>5/8/87</td>
<td>Nonsteroidal Anti-inflammatory Drugs: Clinical, Pharmacologic, Therapeutic and Toxicologic Considerations</td>
<td>Andrew Whelton</td>
</tr>
<tr>
<td>VIII</td>
<td>5/16/88</td>
<td>Clinical Applications of Lipid Lowering Drugs</td>
<td>Andrew Whelton</td>
</tr>
<tr>
<td>X</td>
<td>5/10-5/11/90</td>
<td>Clinical Pharmacology in Space</td>
<td>Claire M. Lathers, John B. Charles</td>
</tr>
<tr>
<td>XI</td>
<td>4/22/91</td>
<td>New Frontiers in Antihypertensive Therapy: Drugs for the 21st Century</td>
<td>Robert W. Piepho</td>
</tr>
<tr>
<td>XII</td>
<td>5/8/92</td>
<td>Pharmacology Beyond Earth’s Boundaries</td>
<td>Claire M. Lathers, John B. Charles, Lakshmi Putcha</td>
</tr>
<tr>
<td>XIII</td>
<td>6/23/93</td>
<td>Frontiers in Women’s Health: The Role of Primary Care</td>
<td>John C. Somberg</td>
</tr>
<tr>
<td>XIV</td>
<td>4/29-4/30/94</td>
<td>Assessing the Pharmacodynamics of CNS-Acting Medications</td>
<td>Frank F. Tellian</td>
</tr>
</tbody>
</table>
Honors and awards sponsored by ACCP are usually conferred at the Annual Meeting of the College. They usually are accompanied by a plaque or certificate and expenses are paid for the recipient to attend the Annual Meeting and receive the award in person. Some of the awardees are asked to present brief talks on their research, service or other basis for the award. At present, only the Young Investigator and McKeen Cattell Awards are accompanied by cash honoraria ($1,000). Decisions on awardees are made by the Honors and Awards Committee, with approval by the Board of Regents. With the exception of the Young Investigators Award, the awards are usually made yearly. A general description of the awards is as follows:

**McKeen Cattell Award** - For the most outstanding clinical research paper published in the Journal of Clinical Pharmacology in any particular year. In 1978, it replaced the Harry Gold Award, which was adopted by ASPET in 1977, as requested by the Gold family. It honors the memory of Dr. McKeen Cattell, first Editor of the Journal of Clinical Pharmacology and one of the original founders of the College.

**Honorary Fellowship Award** - Meant to recognize overall contributions to clinical pharmacology by a senior investigator or individual having a national or international reputation. Usually the award is made to a non-member of the College, and is intended to recognize a lifelong dedication to clinical pharmacology.

**Distinguished Investigator Award** - Intended primarily for scientific expertise and accomplishments for a senior investigator, usually involving a distinct area of research for which the awardee is well known.

**Distinguished Service Award** - Intended for accomplishments of a general nature which benefit clinical pharmacology. May be teaching, administration, service with ACCP, legislative, public affairs or other research or non-research basis.

**Young Investigator Award** - For a young investigator (usually under 40) who has made unusual strides in research relating to clinical pharmacology and whose career shows promise for outstanding accomplishments.
Honorary Fellowship Award

1973 - McKeen Cattell, MD, PhD 1986 - Walter M. Booker, PhD
1975 - Julius Axelrod, PhD 1986 - Louis Lasagna, MD
1976 - Carl F. Schmidt, MD 1986 - Robert E. Vestal, MD
1977 - Harold H. Hodge, PhD 1987 - Walter F. Riker, Jr., MD
1979 - E. Leong Way, PhD 1988 - Robert J. Temple, MD
1980 - John Laragh, MD 1989 - Joseph R. Bertino, MD
1981 - Joseph R. DiPalma, MD 1990 - William F. Chaveas, BS
1982 - George B. Koelle, MD, PhD 1991 - Jerry B. Hook, PhD
1984 - John Chapman, MD 1992 - James A. Boyle, MD
   - James C. Hunt, MD 1993 - Thomas W. Smith, MD
1985 - E. M. Vaughn Williams, D.M. 1994 - Arnold Schwartz, PhD

Distinguished Investigator Award

1988 - Sir James Black, FRCP, FRS 1992 - Victor J. Dzau, MD
1989 - Albrecht Fleckenstein, MD 1993 - Raymond J. Townsend, PharmD
1990 - Harold C. Neu, MD 1994 - Arnold Schwartz, PhD
1991 - Stuart Adams, PhD

Distinguished Service Award

1987 - Francisco Kerdel-Vegas, MD 1990 - Paul A. J. Janssen, MD,PhD
   - Gerhard Levy, PharmD 1991 - John C. Somberg, MD
   - Joseph R. Bianchine, MD, PhD 1992 - James F. Burris, MD
1988 - Leslie Z. Benet, PhD 1993 - Harold C. Neu, MD
1989 - William J. Jusko, PhD 1994 - Milo Gibaldi, PhD

Young Investigator Award

1979 - Robert J. Lefkowitz, MD 1990 - Lawrence G. Miller, MD

Tanabe Young Investigator Award

1992 - David W. Nierenberg, MD
1994 - Scott A. Gruber, MD, PhD
Harry Gold Award

1971 - G. R. Van Petten, PhD
    - R. J. Withey, PhD
1972 - Herbert S. Heineman, MD
1973 - Arthur Lorber, MD
1974 - Mortimer L. Schwartz, MD
1975 - John E. Stambaugh, MD, PhD
1976 - Lowell A. Borgen, PhD

McKeen Cattell Award

1978 - Gerhard Levy, PharmD
1980 - J. Heyward Hull, M.S. Pharm.
1981 - Maysie J. Hughes, PhD
1982 - Thomas L. Biddle, MD
    - H. Weston Moses, MD
1983 - Tove S. Rosen, MD
    - Peter Danilo Jr., MD
1985 - David J. Greenblatt, MD
1986 - Avedis K. Khachadurian, MD
1987 - Martti O. Pulkkinen, MD
1988 - Jeffrey A. Green, PharmD
1989 - Richard D. Schwarz, MD
1990 - William H. Frishman, MD
1991 - Donald D. Denson, PhD
1992 - Fakhreddin Jamali, PhD
1993 - Thomas R. Browne, MD
1994 - Hartmut Derendorf, PhD

Special Recognition Award

1990 - Nathaniel T. Kwit, MD

(This special award was made to Dr. Kwit on the occasion of his leaving the office of Treasurer of the College, after 20 years of service.)